NASDAQ:NLTX

Neoleukin Therapeutics Earnings Date, Estimates & History

$12.21
+0.14 (+1.16 %)
(As of 04/20/2021 12:48 PM ET)
Add
Compare
Today's Range
$12.14
Now: $12.21▼
$12.46
50-Day Range
$11.26
MA: $12.00▼
$13.12
52-Week Range
$9.63
Now: $12.21▼
$18.13
Volume2,696 shs
Average Volume243,740 shs
Market Capitalization$516.80 million
P/E RatioN/A
Dividend YieldN/A
Beta1.09

Earnings

Neoleukin Therapeutics (NASDAQ:NLTX) Earnings Information

Neoleukin Therapeutics last released its earnings data on March 24th, 2021. The reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.21) by $0.03. Neoleukin Therapeutics has generated ($0.75) earnings per share over the last year. Neoleukin Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, May 5th, 2021 based off prior year's report dates.

Neoleukin Therapeutics Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Neoleukin Therapeutics (NASDAQ:NLTX) Earnings Estimates

2021 EPS Consensus Estimate: ($1.25)
2022 EPS Consensus Estimate: ($1.70)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20211($0.25)($0.25)($0.25)
Q2 20211($0.30)($0.30)($0.30)
Q3 20211($0.30)($0.30)($0.30)
Q4 20211($0.40)($0.40)($0.40)
Q1 20221($0.35)($0.35)($0.35)
Q2 20221($0.40)($0.40)($0.40)
Q3 20221($0.45)($0.45)($0.45)
Q4 20221($0.50)($0.50)($0.50)

Neoleukin Therapeutics (NASDAQ NLTX) Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSGAAP EPSRevenue EstimateActual RevenueConference CallDetails
5/5/2021
(Estimated)		       
3/24/202112/31/2020($0.21)($0.24)($0.24)Transcript
11/9/2020Q3 2020($0.21)($0.18)($0.32)N/A
8/12/20206/30/2020($0.21)($0.20)($0.20)Transcript
5/6/20203/31/2020($0.23)($0.18)($0.18)Transcript
3/12/202012/31/2019($0.37)($0.22)($0.23)Transcript
11/13/2019Q3($0.04)($0.44)$1.38N/A
5/7/2019Q1 2019($0.09)($0.09)N/A
3/7/2019Q4 2018($0.20)($0.20)N/A
11/7/2018Q3 2018($0.64)($0.64)N/A
8/8/2018Q2 2018$0.12$0.12$25.00 millionN/A
5/8/2018Q1 2018($0.62)($0.62)N/A
3/12/2018Q4 2017($0.69)($0.69)N/A
11/8/2017Q3 2017($0.62)($0.50)($0.50)N/A
8/8/2017Q2 2017($0.59)($0.59)($0.59)N/A
5/9/2017Q1 2017($0.57)($0.36)($0.36)N/A
3/9/2017Q4 2016($0.63)($0.48)($0.48)N/A
11/9/2016Q3 2016($0.60)($0.46)($0.46)N/A
8/4/2016Q2 2016($0.42)($0.63)($0.63)N/A
5/10/2016Q1 2016($0.35)($0.39)($0.39)N/A
3/14/2016Q4 2015($0.38)($0.27)($0.27)N/A
11/10/2015Q3 2015($0.41)($0.43)($0.43)N/A
8/6/2015Q2 2015($0.49)($0.44)($0.44)N/A
5/12/2015Q1 2015($0.83)($0.60)($0.60)N/A
3/16/2015Q4 2014($0.57)($0.78)($0.78)N/A
11/4/2014Q3 2014($0.29)($0.59)($0.59)N/A
8/11/2014Q2 2014($0.27)($0.51)($0.51)N/A
5/13/2014Q1 2014($1.28)($1.28)N/A
(Earnings results data provided by Zacks Investment Research)
This page was last updated on 4/20/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.